
In large part due to the significant increase in special purpose acquisition company (“SPAC”) formation in the financial markets over the past few years, there has been a similar increase in SPAC-related litigation—most notably in the Delaware Court of Chancery. While some of the suits filed are standard securities class action matters, the more interesting disputes (to the writers of this article, of course) allege breaches of fiduciary duties (i.e., direct action breach of fiduciary class action lawsuits). As of the writing of this article, none of these fiduciary duty suits has been tried to verdict.
The primary focus of the fiduciary litigation is the alleged inaccuracy and insufficiency of public disclosures during the SPAC merger process. SPACs (often referred to as “blank check” companies) raise capital as a vehicle to take private companies public (“de-SPAC” transaction). Generally, the disagreements regarding the public disclosures involve the periods leading up to the de-SPAC transaction. Additionally, premerger SPAC shareholders have alleged that fiduciaries recommended unfair de-SPAC transactions and that SPAC insiders engaged in self-dealing.
SPACs Explained
On January 24, 2024, the Securities and Exchange Commission (“SEC”) published Final Rule S7-13-22, with the stated purpose of “enhanc[ing] investor protections in initial public offerings by special purpose acquisition companies . . . and in subsequent business combination transactions between SPACs and private operating companies.”[1] In that rule, the SEC defined SPACs as follows: “[S]pecial purpose acquisition companies . . . are shell companies organized and managed by a sponsor for the purpose of merging with or acquiring one or more unidentified private operating companies, commonly known as a de-SPAC transaction, within a certain time frame.”[2]
SEC Final Rule S7-13-22 continues to state:
The de-SPAC transaction is a hybrid transaction that contains elements of both an initial public offering . . . and a merger and acquisition . . . transaction. While structured as an M&A transaction, the de-SPAC transaction also is the functional equivalent of the private target company’s IPO, because it results in the target company becoming part of a combined company that is a reporting company and provides the private target company with access to cash proceeds that the SPAC had previously raised from the public. As part of this process, the shareholders of the SPAC go from owning shares in the shell company to owning shares in a combined company that conducts the business of the private target. As a result, the de-SPAC transaction implicates disclosure and liability concerns associated with both IPOs and M&A transactions.[3]
The SEC also sets forth the following regarding the structure and life cycle of a SPAC:
- SPAC initial public offering (“IPO”): Once formed, a SPAC will conduct its IPO in the form of a firm commitment underwritten IPO of $5 million or more in units consisting of redeemable shares and of warrants.[4]
- IPO proceeds placed in escrow: Following its IPO, a SPAC places all or substantially all of the IPO proceeds into a trust or escrow account.[5]
- Trading period: Typically, the SPAC registers its shares and warrants under section 12(b) of the Securities Exchange Act of 1934 (“Exchange Act”) and lists the units for trading on a national securities exchange.[6]
- Target identification: Next, the SPAC seeks to identify a target company for a de-SPAC transaction within the time frame specified in its governing documents. The governing documents often provide a time frame of twenty-four months, but it can be as long as thirty-six months. If the SPAC does not complete the de-SPAC transaction within that time frame, it may seek an extension or dissolve and liquidate.[7]
- Merger announcement: If the SPAC enters into a business combination agreement with a target company, the SPAC files a Form 8-K announcing the transaction and detailing certain information on the material terms of the business combination agreement.[8]
- Shareholder vote: Prior to the closing of the de-SPAC transaction, the shareholders of the SPAC typically have the opportunity to either (a) require the SPAC to redeem their shares and receive a pro rata share of the amount in the IPO proceeds and related assets held in trust or escrow or (b) remain a shareholder of the surviving company after the business combination.[9]
- Private investment in public equity (“PIPE”) financing: In order to offset aforementioned shareholder redemptions, or to fund larger de-SPAC transactions, SPACs often conduct additional private capital-raising transactions, typically in the form of PIPE transactions.[10]
- Proxy statement filing: Generally, shareholder approval is required for certain relevant items during the de-SPAC transaction (e.g., amendments to the governing documents of the SPAC or authorization of additional securities for issuance). In such instances, a SPAC provides its shareholders with a proxy statement on Schedule 14A of an information statement on Schedule 14C.[11]
- Tender offer: After issuances of required registration and proxy statements, the SPAC may disseminate a tender offer statement for the redemption offer to its security holders with information about the target company.[12]
- Merger completion / de-SPAC transaction: After the completion of the de-SPAC transaction, the combined company must file a Form 8-K within four business days that includes information about the target company equivalent to the information that a new reporting company would be required to provide when filing a Form 10 under the Exchange Act.[13]
For the purposes of the fiduciary duty litigation, relevant actions occur between step #5 (merger announcement) and step #9 (tender offer) noted above. It is during this time period when SPAC shareholders evaluate the accuracy and sufficiency of public disclosures made by the SPAC sponsors. Specifically, at this time, the SPAC shareholders rely on the aforementioned disclosures to inform their decision about whether to opt into the merger or redeem their shares at par value plus interest.
Important SPAC Decisions
Denial of Motion to Dismiss: In re MultiPlan Corp. Stockholders Litigation
In the first decision to test Delaware fiduciary principles in a de-SPAC context, Vice Chancellor Lori Will denied a motion to dismiss and applied entire-fairness review to the MultiPlan merger, concluding that the sponsor’s “founder shares” and the board’s parallel incentives created a disabling conflict, and that materially incomplete disclosures deprived public stockholders of a fully informed choice about whether to redeem at the $10-per-share trust value or remain invested.[14] The court framed the harm as a direct injury to each investor’s personal redemption right (and not, as in most mergers and acquisitions (“M&A”) litigation, a derivative injury) and confirmed that SPAC fiduciaries owe the traditional duty of candor even though investors already possess the contractual right to exit. Although the merits never reached trial, the parties settled for $33.75 million, now an informal reference point for valuing “MultiPlan claims.”
Dismissal: In re Hennessy Capital Acquisition Corp. IV Stockholder Litigation
In this decision, the Delaware Court of Chancery delivered the first post-MultiPlan dismissal of a SPAC fiduciary-duty suit, underscoring that entire-fairness scrutiny does not relax Delaware’s pleading standards.[15] Vice Chancellor Will noted in that case that, after the MultiPlan decision, “SPAC lawsuits are ubiquitous in Delaware.”[16] The court held that sponsor conflicts and a steep post-merger price decline, standing alone, cannot sustain a claim; plaintiffs must allege specific, knowable omissions that actually distorted the redemption decision. Because Canoo’s strategic overhaul took place only after the merger and there were no well-pled facts showing that the SPAC fiduciaries knew of undisclosed problems pre-closing, the complaint failed.
More Recent Case: Solak v. Mountain Crest Capital
On October 18, 2024, the Delaware Court of Chancery denied the defendants’ motion to dismiss in a failure-to-disclose matter even though the court stated that the allegations were “not strong” as compared with other SPAC cases that survived motions to dismiss.[17] In this matter, John Solak v. Mountain Crest Capital, LLC, the defendant raised $57.5 million through an IPO on January 8, 2021. On April 7, 2021, the defendant announced a merger agreement with Better Therapeutics.
The defendant filed with the SEC and issued proxy statements to shareholders to approve the merger on October 12, 2021. The shareholder vote meeting was scheduled for October 27, 2021, and the deadline to redeem shares was October 25, 2021. The proxy statement valued the shares at $10, but the dilution of the redemptions and founder shares, along with the costs of the merger, reduced the actual cash balance to less than $7.50 per share.
Investors Split into Two Groups: In re InterPrivate
The shareholder complaint in the In re InterPrivate litigation[18] shows how potential divergent shareholder class interests play out when investors split into two economically divergent groups. In the 2024 complaint, plaintiffs say the sponsor and directors steered the merger with Aeva, masked problems, and thereby impaired a fair redemption decision. The complaint adds an allegation that the price was misleading and that the value of what was purchased was not $10 per share but instead $8.50 after taking into account cash dilution as a result of the merger.
But roughly 50 percent of the issued and outstanding shares in fact redeemed at $10.20 (“Redemption Class”). Others kept (or later sold) shares that soon traded below $3 after trading at $16.16 the first day of trading (“Market-Loss Class”). The case appears headed toward settlement as of the time of this writing but presents interesting issues for consideration for damages estimation in this new twist on the MultiPlan line of cases.
Why InterPrivate Complicates Damages and Class Structure
Two economic cohorts:
- The Redemption Class claims it was tricked out of the secure $10 trust value and therefore seeks rescissory damages measured against that floor.
- The Market-Loss Class alleges classic stock-drop harm, typically quantified with an event-study anchored in the price at the time of post-merger corrective disclosures.
Typicality and predominance questions:
Because the Redemption Class and the Market-Loss Class rely on different valuation baselines, the defendants argued that Rule 23 requires separate subclasses with distinct experts and damage models; otherwise, the predominance of common issues breaks down, and the named plaintiff may not be typical of both groups.
SPAC Damages and Open Questions
SPAC damages present a unique twist on estimation of damages in Delaware fiduciary cases. The presence of the redemption option and the subsequent outcome in share price present the potential for two different estimates to exist in tension. Forensic accountants can help litigators navigate those tensions with the following general principles:
- Redemption-floor model. This model focuses on the potential damages to the Redemption Class. Lost-redemption damages equal (Trust-per-share + interest – actual disposition price) × shares. The analyst must confirm each holder’s election record and any interest earned in trust. Prejudgment interest is then subsequently applied.
- Market-loss model. This model focuses on potential damages to the Market-Loss Class. Apply an event-study to isolate price inflation attributable to the undisclosed facts at closing; then measure decline when the truth emerges (often the first post-merger corrective disclosure). Prejudgment interest is then subsequently applied.
If subclasses are required, experts must run both models and provide the court with parallel damages schedules. If a single class survives, experts should still show how aggregate damages decompose by cohort to aid plan-of-allocation negotiations and fairness-hearing scrutiny.
The following open questions remain:
- Will Delaware approve an all-in settlement when cohorts’ economic interests diverge?
- How will judgment offsets be calculated when some investors already recovered $10 through redemption?
- Will future SPAC litigants plead around InterPrivate by appointing separate subclass representatives at the outset, or will they instead focus pleading on only the Redemption Class?
Together, MultiPlan sets the fiduciary-duty and entire-fairness framework, while InterPrivate spotlights the practical valuation and certification hurdles that arise once redeeming and nonredeeming investors pursue the same direct claim.
Conclusion
The rise of SPACs was a unique phenomenon in corporate and securities law, and just as a wave of Delaware SPAC litigation from the 2020–2021 SPAC wave makes its way through Delaware courts, another wave of major SPAC deals is emerging. This article can serve as a guide to help litigators and forensic accountants navigate the unique fiduciary and damages issues in SPAC matters.
Appendix: Case Status Cheat Sheet
While many Delaware SPAC cases are pending, the chart below provides a representative sample of some of the more significant open SPAC matters in Delaware and summarizes the questions at issue and case status for each.
Case | Stage | Key Remedy/Issue | Latest Move |
In re MultiPlan Corp. S’holders Litig. | Settled (Oct. 2024). | $33.75 million cash; direct claim for impairment of redemption right. | Settlement approved; sets headline valuation for future risk. Source: The D&O Diary. |
In re Hennessy Cap. Acquisition Corp. IV Stockholder Litig. | Dismissed at pleadings (May 2024); first full defense win post-MultiPlan. | Court found no well-pled disclosure violation, and thus no redemption-right impairment. | Plaintiffs filed notice of appeal (pending). Source: Hogan Lovells. |
In re Skillsoft S’holders Litig. | Dismissed pre-discovery (Feb. 2025) under entire-fairness. | VC Laster found no nonratable benefit to sponsor. | Motion for reargument denied April 1, 2025. Source: Enhanced Scrutiny. |
Smith v. Fattouh (InterPrivate/Aeva) | Putative class action; term-sheet for $14 million global settlement signed July 2, 2024 (court approval pending). | Claims mirror MultiPlan but raise two-track damages problem: (i) redeemers capped at trust ~$10; (ii) market purchasers allege drop-based damages. | Settlement agreement reached. Source: InterPrivate Stockholder Settlement information page. |
Mountain Crest v. Better Therapeutics | Motion-to-dismiss denied (Oct. 2024). | New theory: nondisclosure of net cash per share; court allowed claim to proceed. | Settlement agreement. Source: Morningstar. |
Trident/Lottery.com | $2.6 million settlement preliminarily approved Nov. 2024. | Complaint highlights difficulty of a single class when some holders redeemed at $10 while others later sold into a collapse. | Settlement hearing scheduled for June 2025. See Weisheipl v. Rosenberg, N. 2023- (Apr. 3, 2023). Sources: Law360; The D&O Diary. |
SEC Final Rule S7-13-22, at 1 (Jan. 24, 2024). ↑
Id. at 8. ↑
Id. at 8–9. ↑
Id. at 9. ↑
Id. at 10. ↑
Id. ↑
Id. at 10, n.12. ↑
Id. at 10–11. ↑
Id. at 11. ↑
Id. ↑
Id. at 11, 12. ↑
Id. at 12. ↑
Id. at 13. ↑
In re MultiPlan Corp. Stockholders Litig., No. 2021-0300-LWW (Del. Ch. Jan. 3, 2022). ↑
In re Hennessy Cap. Acquisition Corp. IV S’holder Litig., No. 2022-0571-LWW (Del. Ch. May 31, 2024). ↑
Id. at 1. ↑
John Solak v. Mountain Crest Cap. LLC, No. 2023-0469-SG (Oct. 18, 2024). ↑
Katz v. Fattouh (In re InterPrivate), No. 2024-0598-LWW (June 6, 2024); see also Aeva Techs., Inc., Form 10-Q, at n.14 (quarterly period ended Mar. 31, 2024) (contemporaneous description of the In re InterPrivate litigation). ↑










